Genmab — Februar 2023
-
We also anticipate regulatory approvals this year for epcoritamab in relapsed refractory large B-cell lymphoma in several major geographies, including the U.S. in the second quarter and in Europe and Japan in the second half of the year.
Based on the very deep and durable responses demonstrated thus far in our clinical program, we believe that epcoritamab has the potential to significantly improve upon treatment options for these patients.
-
We believe that epcoritamab has the potential to become a core therapy for B-cell malignancies. And we continue to make very good progress expanding our development programs for epcoritamab across several indications. Over the course of 2023, we expect to begin several new studies, including a phase 3 study in front-line DLBCL in combination with R-CHOP and multiple phase 2 studies in CLL and MCL.
-
Der blev lidt stille! Men det er ds godt nok også et voldsomt pres på idag…:-(
-
Nyder stilheden og roen
Helge har sikkert en anden opfattelse af den manglende trafik herinde. Solgte i øvrigt en pæn bid i går og genkøbt i dag. -
-
JKY
-
LLI...Vi har masser af besøgende i dag, men som altid er der mindre lyst til at skive i
debat og chat, når markederne er røde.
-
Men som tidligere nævnt er Genmab p.t en lækkerbidsken for big pharma m.h.t opkøb p.g.a den historisk lave prisætning p.t ca. PE30. Det er ikke længe siden Genmab blev handlet over PE70 (2021 kurs 3100) og et evt. opkøb omkring PE70 svare idag til kurs ca. 5500.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind